An Account Representative’s Perspective: Five Key Things I Learned from Being Treated with PROKERA


As an account representative for Bio-Tissue, I look forward to visiting with doctors and staff and talking about the benefits of PROKERA. However, when I recently became a patient, I learned even more about the benefits of this biologic corneal bandage with cryopreserved amniotic membrane. This experience not only helped heal my ocular surface, but also provided valuable information I can pass on to doctors and staff.

Ways to Educate our Dry Eye Patients and Make Them More at Ease


Our practice has always had a strong focus on cataract surgery, and from its inception has been at the forefront of treating patients with dry eye disease (DED). Early on, we realized the importance of having a healthy ocular surface for our patients prior to surgery. As such, all of us within the practice pay particular attention when treating patients with DED. We are very fortunate to have the most up-to-date equipment and tools available to help these patients.

"Why Intervene/5 D's” Reference Guide Now Available Online


To support doctors using PROKERA and inform others who may be interested in implementing Bio-Tissue’s biologic corneal bandage device in your practice, we recently made our "Why Intervene/5 D's" reference guide available to everyone online. This handy guide provides a quick reference to various indications where PROKERA provides clinical value, and we received such positive feedback to the print version that we decided to offer it electronically.

A Protocol for Use of PROKERA after Corneal Collagen Cross-Linking


With the Federal Drug Administration (FDA) approval of corneal collagen cross-linking (CXL) (Avedro, April 2016) for the treatment of progressive keratoconus, we can expect to see a high volume of these procedures being done by corneal specialists. Although the disease is considered rare, which according to the National Eye Institute (NEI) affects approximately one in every 2,000 Americans, the disease can lead to blindness if not treated. As we know, the surgical technique for performing CXL that is FDA-approved for use in the U.S. at this time is epithelium-off (epi-off, Dresden protocol).

Part 2: Amniotic Membrane Speeds Healing


In part one of a two-part series, Josh Johnston, OD discussed the paradigm shift in treating patients with dry eye. Here, he speaks to Primary Care Optometry News (PCON) about cryopreserved amniotic membrane and how it speeds healing.

In his last blog, Josh Johnston, OD, Georgia Eye Partners, spoke about the “Paradigm Shift in Treating Patients with Dry Eye” and how the introduction of new therapies allows doctors to provide better outcomes to patients and improve clinical outcomes. One of the therapies he spoke of is PROKERA with cryopreserved amniotic membrane, and its many benefits particularly for those patients with corneal involved dry eye.

Part 1: The Paradigm Shift in Treating Dry Eye


In part one of a two–part series, Josh Johnston, OD discusses the paradigm shift in treating patients with dry eye.

Treating dry eye disease (DED) has truly evolved over the past years, and even more so recently with new diagnostics, therapies and FDA-approved drugs. We all know DED is progressive and can be hard to treat, which is actually one of the reasons I like it so much. It’s an exciting time for those of us treating DED. The paradigm shift has changed and there are new, novel products and therapies at our disposal that allow us to provide better options to patients and improve clinical outcomes.

Bio-Tissue’s Dry Eye Center of Excellence Program


Our company’s groundbreaking scientific research in the study of regenerative medicine has led to the development of innovative products that are used worldwide by eye care professionals to treat ocular surface disease (OSD), including dry eye. In order to help you leverage our products, elevate the level of care you provide to your patients, improve clinical outcomes, and grow your practice, we developed the Dry Eye Center of Excellence Program (DECE).

Part 2: The Business Impact of Offering Cliradex in Your Practice


In part two of her series, Patti Barkey, CEO, Bowden Eye & Associates, in Jacksonville, Fla., discusses how Cliradex has assisted in practice efficiency, clinical outcomes and how it has improved business and their bottom line.

Part 1: The Business Impact of Offering Cliradex in Your Practice


In part one of a two-part series, Patti Barkey, CEO, Bowden Eye & Associates, in Jacksonville, Fla., discusses why they decided to implement Cliradex in their practice, how it fits into their “Dry Eye Disease" toolbox, and how it is used.

Research to be Presented at ASCRS that Further Demonstrates Effectiveness of Cryopreserved Amniotic Membrane for Ocular Surface Healing


This week we issued a press release announcing the presentation of key research at this week’s American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, May 5-9. This research further demonstrates the clinical effectiveness of PROKERA, our biologic corneal bandage with cryopreserved amniotic membrane tissue.